Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 7/20 | 0.43 |
| ▸ | HTR6 | P50406 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310291 | 0.82 | HTR6 (0.40) | SIGMAR1HTR2CHTR6KDM4EALDH1A1 | |
| SCHEMBL6310625 | 0.82 | HTR2C (0.49) | SIGMAR1HTR2CHTR6KDM4EALDH1A1 | |
| SCHEMBL15450945 | 0.67 | CYP1A2 (0.51) | KDM4EALDH1A1MAPTHTR2AHTT | |
| SCHEMBL4359561 | 0.67 | HTR2C (0.54) | SIGMAR1HTR2CHTR6KDM4EALDH1A1 | |
| SCHEMBL6313007 | 0.66 | MEN1 (0.43) | SIGMAR1HTR2CHSD17B10CYP1A2CYP2D6 | |
| SCHEMBL21862220 | 0.64 | MIF (0.47) | KDM4EALDH1A1MAPTHSD17B10CYP1A2 | |
| SCHEMBL4359750 | 0.64 | SIGMAR1 (0.50) | SIGMAR1HTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL5760127 | 0.64 | HTR2C (0.43) | SIGMAR1HTR2CHTR6KDM4EALDH1A1 | |
| SCHEMBL14045624 | 0.64 | CNR2 (0.46) | KDM4EALDH1A1HTR2AHSD17B10CYP1A2 | |
| SCHEMBL9974662 | 0.63 | HTR2C (0.59) | SIGMAR1HTR2CHTR6QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844344-B2 | Benzofuran derivatives | ELI LILLY AND COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| US-6784180-B2 | INHIBITING THE REUPTAKE OF SEROTONIN AND ANTAGONIZING THE 5-HT1A RECEPTOR; AS ANTIDEPRESSANT OR TO POTENTIATE EFFECTS OF ANOTHER SSRI | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| EP-1250336-B1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030232833-A1 | Benzofuran derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030225281-A1 | Piperidines derivatives and their use as serotonin receptor antagonists | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225281-A1 | Piperidines derivatives and their use as serotonin receptor antagonists | HTR1A, HTR1D, HTR5A | SIGMAR1 173/4885HTR2C 7/4885HTR6 11/4885 |
| US-20030232833-A1 | Benzofuran derivatives | BRD1, BPTF, HTR1F | SIGMAR1 789/4885HTR2C 52/4885HTR6 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.